The Patent Finder

Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use

Adimab, LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2017/057737, filed Oct 20, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,281,156Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use
In force
 · High confidence
Adimab, LLCIn force
High confidence
US 11,485,775Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use
In force
 · High confidence
Adimab, LLCIn force
High confidence
Application 19/083,503Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use
Pending
Not granted
Adimab, LLCPendingNot granted
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Adimab, LLC.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited